Clinical trials: Elderly Population
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Covid19
Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)
This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy…
- Trial name
- COSMIC (NCT05280717)
- Testing
- sotrovimab
- Where
- 10 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Frail Elderly Syndrome, Surgery
Development and Validation of a Preoperative Frailty Index Using Health Administrative Data
The investigators will create a frailty index using health administrative data available for older people having surgery. The index will be based on the Canadian Study of Health and Aging Frailty Index and standard…
- Conditions
- Frail Elderly Syndrome, Surgery, Outcomes, Predictive Value of Tests
- Trial name
- NCT03354546
- Testing
- Frailty index
- Volunteers
- 511,285 people
- Sponsor
- Ottawa Hospital Research Institute
Aging
Affordable Mobile Robots for the Elderly
This project develops and tests the use of service robots to track health of the elderly over time. The objectives are to develop a low-cost mobile manipulator capable of a limited set of elder- relevant manipulation tasks (e.g.
- Trial name
- NCT02807506
- Testing
- Mobile Service Robot, Survey
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Fall, Fear of Falling
Optimizing a Technology-based Body and Mind Intervention
Older adults may feel at risk for falling, but do not have a physical risk of falling. On the other hand, some older adults may not feel at risk for falling, but do have a physical risk of falling.
- Conditions
- Fall, Fear of Falling, Physical Inactivity, Sedentary Behavior
- Trial name
- NCT05778604
- Testing
- Physio-feedback, Cognitive reframing, Peer-led exercises
- Where
- United States
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Overactive Bladder (OAB)
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
- Trial name
- PILLAR (NCT02216214)
- Testing
- Mirabegron
- Where
- 120 sites in United States, Canada
- Volunteers
- 888 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Glaucoma, Retinal Disease
The EASE Study - Human Factor and Usability Testing of a Binocular OCT System
Ophthalmology is among the most technology driven of all medical specialties, with advanced medical imaging devices - and specialised computer software - increasingly adopted for routine clinical use.
- Conditions
- Glaucoma, Retinal Disease, Strabismus, Healthy Volunteers
- Trial name
- EASE (NCT02822612)
- Testing
- Binocular OCT prototype
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University College, London
Major Depressive Disorder
Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve depressive symptoms in elderly patients with major…
- Trial name
- NCT00388973
- Testing
- Quetiapine
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 338 people
- Sponsor
- AstraZeneca
Hypertension
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
- Trial name
- NCT00706134
- Testing
- Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg
- Where
- 8 sites in Argentina, Czechia and 6 more
- Volunteers
- 756 people
- Sponsor
- Novartis
Binge Eating Disorder
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by…
- Trial name
- NCT01718509
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 48 sites in United States, Germany
- Volunteers
- 390 people
- Sponsor
- Shire
Hepatitis B Vaccine
Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.
The purpose of this study is to assess the persistence of immunity to hepatitis B in children who received three consecutive doses of HBV vaccine (EngerixTM-B) in infancy.
- Trial name
- NCT00519649
- Testing
- Engerix™-B Kinder
- Where
- 35 sites in Germany
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers
The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune…
- Trial name
- NCT01229371
- Testing
- Inflexal V influenza vaccine (CSL HA Antigen) 2010, Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011
- Where
- 2 sites in Switzerland
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Cystic Fibrosis
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the…
- Trial name
- NCT02412111
- Testing
- Ivacaftor, Tezacaftor/Ivacaftor
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 156 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
ADHD
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.
- Trial name
- NCT00763971
- Testing
- Lisdexamfetamine Dimesylate (LDX), Methylphenidate Hydrochloride
- Where
- 49 sites in Belgium, France and 8 more
- Volunteers
- 336 people
- Sponsor
- Shire
Influenza
Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years
A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged >= 6 Months to < 18 Years
- Trial name
- NCT00825162
- Testing
- CSL Limited Influenza Virus Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 1,992 people, healthy volunteers welcome
- Sponsor
- Seqirus
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-1 (NCT03349060)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 387 people
- Sponsor
- Pfizer
Insomnia Disorder
Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
Study to assess the long term safety and tolerability of daridorexant in adult and elderly subjects suffering from difficulties to sleep
- Trial name
- NCT03679884
- Testing
- Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg
- Where
- 106 sites in United States, Belgium and 12 more
- Volunteers
- 804 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Presbyopia
A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily
Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations.
- Trial name
- Virgo (NCT04983589)
- Testing
- Pilocarpine HCl, Vehicle
- Where
- 23 sites in United States
- Volunteers
- 230 people
- Sponsor
- Allergan
Attention Deficit Hyperactivity Disorder
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B).
- Trial name
- NCT04085172
- Testing
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
- Where
- 50 sites in United States, Austria and 7 more
- Volunteers
- 396 people
- Sponsor
- Shire
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.
- Trial name
- EXIST-2 (NCT00790400)
- Testing
- Everolimus (RAD001)
- Where
- 25 sites in United States, Canada and 9 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals